Source: The Motley Fool
“We will go for regulatory approvals in October.”
Those were the words ofPfizer(NYSE:PFE)CEO Albert Bourla in aWashington Postlive interview earlier this month. He was referring to the prospect that the company, along with its partnerBioNTech(NASDAQ:BNTX), could seek approval for COVID-19 vaccine candidate BNT162b2 in the near future.
This statement was consistent with Bourla’s previous comments. In July, for example, he toldTimemagazine that Pfizer expected to know in September whether or not its vaccine works. He added that would pave the way for a quick Food and Drug Administration submission and even approval in October “if we are lucky.”
Is this timeline really attainable? There’s another reason now to believe that Pfizer just might have…
View original post 680 more words